Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of May 2023. The report, dated May 3, 2023, serves as a vehicle to disseminate a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing a press release but does not include revenue, profit, cash flow, margins, debt, or liquidity figures within the text itself.
Material Changes
The filing text does not provide details on material changes versus prior periods. The content is limited to the submission of a press release dated May 3, 2023, without summarizing the specific operational or financial changes contained therein.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the provided text. The document only confirms the authorization of the report by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
Key Facts for Investor Verification
- Verify the content of the referenced Press Release (Exhibit 99.1) dated May 3, 2023, as the specific news or data is not summarized in this filing text.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that no financial metrics are disclosed in this specific document; investors must refer to the attached exhibit or subsequent financial reports for quantitative data.